ATE305313T1 - Radiotherapy - Google Patents

Radiotherapy

Info

Publication number
ATE305313T1
ATE305313T1 AT01945519T AT01945519T ATE305313T1 AT E305313 T1 ATE305313 T1 AT E305313T1 AT 01945519 T AT01945519 T AT 01945519T AT 01945519 T AT01945519 T AT 01945519T AT E305313 T1 ATE305313 T1 AT E305313T1
Authority
AT
Austria
Prior art keywords
bone
tumors
human
subject
treatment
Prior art date
Application number
AT01945519T
Other languages
English (en)
Inventor
Roy H Larsen
Gjermund Henriksen
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta As filed Critical Algeta As
Application granted granted Critical
Publication of ATE305313T1 publication Critical patent/ATE305313T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT01945519T 2000-07-04 2001-07-04 Radiotherapy ATE305313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika
PCT/GB2001/002996 WO2002005859A2 (en) 2000-07-04 2001-07-04 Radiotherapy

Publications (1)

Publication Number Publication Date
ATE305313T1 true ATE305313T1 (de) 2005-10-15

Family

ID=19911348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945519T ATE305313T1 (de) 2000-07-04 2001-07-04 Radiotherapy

Country Status (15)

Country Link
US (2) US7056275B2 (de)
EP (1) EP1296722B1 (de)
JP (1) JP5219325B2 (de)
KR (1) KR100892002B1 (de)
AT (1) ATE305313T1 (de)
AU (2) AU6773401A (de)
CA (1) CA2413736C (de)
CZ (1) CZ299087B6 (de)
DE (1) DE60113683T2 (de)
DK (1) DK1296722T3 (de)
EA (1) EA004899B1 (de)
ES (1) ES2250419T3 (de)
NO (1) NO313180B1 (de)
PL (1) PL206209B1 (de)
WO (1) WO2002005859A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
CA2381123C (en) * 2000-02-25 2011-10-04 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6670456B2 (en) 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
EA008195B1 (ru) * 2003-04-15 2007-04-27 Алгета Ас Применение тория-227 в лучевой терапии заболеваний мягких тканей
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
AU2005215234B2 (en) * 2004-02-20 2009-02-19 Algeta As Alpha-emitting Hydroxyapatite particles
LU91085B1 (en) * 2004-06-25 2005-12-27 European Community Radionuclides for medical use.
US7794691B2 (en) 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
AU2005259258B2 (en) * 2004-06-25 2010-11-25 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US8557601B2 (en) 2006-07-10 2013-10-15 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
FR2913970B1 (fr) * 2007-03-19 2009-06-12 Cogema Production de thorium 228 a partir d'un sel de thorium naturel
WO2008124778A2 (en) * 2007-04-09 2008-10-16 George Fred Harder Hybrid source containing multi-radionuclides for use in radiation therapy
US9273059B2 (en) 2009-08-24 2016-03-01 Lumiphore, Inc. Macrocyclic HOPO chelators
EP3263562A1 (de) * 2009-12-24 2018-01-03 Lumiphore, Inc. Radiopharmazeutische komplexe
US9202602B2 (en) 2010-02-10 2015-12-01 Uchicago Argonne, Llc Production of isotopes using high power proton beams
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
GB201600161D0 (en) 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
CN108778347A (zh) 2016-03-24 2018-11-09 拜耳制药股份公司 放射性药物配合物
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
KR102560243B1 (ko) 2017-05-11 2023-07-27 알파 타우 메디컬 리미티드 근접치료 디바이스용 폴리머 코팅
AU2019247818B2 (en) 2018-04-02 2021-10-14 Alpha Tau Medical Ltd. Controlled release of radionuclides
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
WO2020180756A1 (en) * 2019-03-01 2020-09-10 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
EP4003959A1 (de) 2019-07-25 2022-06-01 Bayer AS Zielgerichtete radiopharmazeutika zur diagnose und behandlung von prostatakrebs
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата
WO2022130195A1 (en) 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment
KR102545315B1 (ko) 2021-01-05 2023-06-20 한국과학기술원 의료용 방사성 동위원소의 생산 방법 및 시스템

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2329147A (en) * 1938-05-07 1943-09-07 Rare Chemicals Inc Stabilized metal sol and method of preparing same
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
EP1191948A2 (de) * 1999-06-11 2002-04-03 Neorx Corporation Hochdosierte radionuklide komplexe zur knochenmark-unterdrückung
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
CA2381123C (en) * 2000-02-25 2011-10-04 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
US20060135842A1 (en) 2006-06-22
PL206209B1 (pl) 2010-07-30
NO20003457D0 (no) 2000-07-04
US20030166989A1 (en) 2003-09-04
US7335154B2 (en) 2008-02-26
KR100892002B1 (ko) 2009-04-07
NO313180B1 (no) 2002-08-26
EP1296722A2 (de) 2003-04-02
DE60113683T2 (de) 2006-07-06
AU2001267734B2 (en) 2005-09-01
EA200201258A1 (ru) 2003-06-26
PL366070A1 (en) 2005-01-24
WO2002005859A2 (en) 2002-01-24
JP2004503331A (ja) 2004-02-05
EP1296722B1 (de) 2005-09-28
KR20030029100A (ko) 2003-04-11
DK1296722T3 (da) 2006-02-13
AU6773401A (en) 2002-01-30
US7056275B2 (en) 2006-06-06
DE60113683D1 (en) 2006-02-09
WO2002005859A3 (en) 2002-09-06
CA2413736C (en) 2009-08-18
CZ299087B6 (cs) 2008-04-23
NO20003457L (no) 2002-01-07
CA2413736A1 (en) 2002-01-24
EA004899B1 (ru) 2004-08-26
JP5219325B2 (ja) 2013-06-26
ES2250419T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
ATE305313T1 (de) Radiotherapy
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
TR200102707T2 (tr) AĞrì hafifletme, kemik kanseri terapisi ve kemik yzeyinin saĞlìklì tutulmasì i‡in kire‡lenmiç hedef dokulara y”nelik radyum-223 hazìrlanmasì ve kullanìmì.
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
DE60324448D1 (de) Brachytherapievorrichtung
DE60225702D1 (de) Strontium verbindung zur behandlung von sub-dermalem weichteilschmerz
EP1778351A4 (de) Verifizierung von läsionsmerkmalen mit strahlformen
BRPI0607460A2 (pt) braquiterapia periférica de órgãos protrusos moldáveis
PL1750596T3 (pl) Element łączący do wprowadzania do środka struktury kostnej ciała człowieka lub zwierzęcia i związany z nim system lokalizujący
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
Levendag et al. A new applicator design for endocavitary brachytherapy of cancer in the nasopharynx
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
AR031641A1 (es) Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
BR112022026094A2 (pt) Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
NO20064232L (no) Alfa.emitterende hydroksyapatittparikler
MXPA05006722A (es) Metodo para tratamiento de pacientes con exposicion a radiacion.
MXPA06014266A (es) Agentes de diagnostico para formacion de imagenes por emision de positrones utilizando xantenos halogenados radioetiquetados y metodos para la formacion de imagenes por emision de positrones con agentes de diagnostico de xantenos halogenados radioeti
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
DE502004012439D1 (de) Medikament und verwendung zur tumortherapie
UA11383U (uk) Спосіб терапії хворих на рак щитовидної залози з множинними метастазами в скелет

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296722

Country of ref document: EP